These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 35464283)

  • 1. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
    Sun HC; Zhou J; Wang Z; Liu X; Xie Q; Jia W; Zhao M; Bi X; Li G; Bai X; Ji Y; Xu L; Zhu XD; Bai D; Chen Y; Chen Y; Dai C; Guo R; Guo W; Hao C; Huang T; Huang Z; Li D; Li G; Li T; Li X; Li G; Liang X; Liu J; Liu F; Lu S; Lu Z; Lv W; Mao Y; Shao G; Shi Y; Song T; Tan G; Tang Y; Tao K; Wan C; Wang G; Wang L; Wang S; Wen T; Xing B; Xiang B; Yan S; Yang D; Yin G; Yin T; Yin Z; Yu Z; Zhang B; Zhang J; Zhang S; Zhang T; Zhang Y; Zhang Y; Zhang A; Zhao H; Zhou L; Zhang W; Zhu Z; Qin S; Shen F; Cai X; Teng G; Cai J; Chen M; Li Q; Liu L; Wang W; Liang T; Dong J; Chen X; Wang X; Zheng S; Fan J;
    Hepatobiliary Surg Nutr; 2022 Apr; 11(2):227-252. PubMed ID: 35464283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview.
    Sun HC; Zhu XD
    Front Oncol; 2021; 11():772195. PubMed ID: 34869008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.
    Zhao HT; Cai JQ
    World J Gastroenterol; 2021 Dec; 27(47):8069-8080. PubMed ID: 35068855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
    Kudo M; Kawamura Y; Hasegawa K; Tateishi R; Kariyama K; Shiina S; Toyoda H; Imai Y; Hiraoka A; Ikeda M; Izumi N; Moriguchi M; Ogasawara S; Minami Y; Ueshima K; Murakami T; Miyayama S; Nakashima O; Yano H; Sakamoto M; Hatano E; Shimada M; Kokudo N; Mochida S; Takehara T
    Liver Cancer; 2021 Jun; 10(3):181-223. PubMed ID: 34239808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.
    Zhang Z; Zhang E
    Front Immunol; 2023; 14():1073531. PubMed ID: 37180144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities.
    Wang MD; Xu XJ; Wang KC; Diao YK; Xu JH; Gu LH; Yao LQ; Li C; Lv GY; Yang T
    Cancer Sci; 2024 Jul; 115(7):2159-2169. PubMed ID: 38695305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.
    Bai J; Huang M; Song B; Luo W; Ding R
    Technol Cancer Res Treat; 2023; 22():15330338231159718. PubMed ID: 36855803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.
    Chen QF; Chen S; Chen M; Lyu N; Zhao M
    J Clin Transl Hepatol; 2024 Mar; 12(3):298-304. PubMed ID: 38426191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma.
    Takamoto T; Maruki Y; Kondo S
    Expert Opin Pharmacother; 2023; 24(14):1567-1575. PubMed ID: 37357809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.
    Yau T; Tai D; Chan SL; Huang YH; Choo SP; Hsu C; Cheung TT; Lin SM; Yong WP; Lee J; Leung T; Shum T; Yeung CSY; Tai AY; Law ALY; Cheng AL; Chen LT
    Liver Cancer; 2022 Sep; 11(5):426-439. PubMed ID: 36158587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
    Yang Y; Sun J; Wu M; Lau WY; Zheng S; Wang XH; Chen X; Fan J; Dong J; Cai J; Chen M; Chen Y; Cheng Z; Dai C; Shan J; Du CY; Fang C; Hu H; Ji Z; Jia W; Li G; Li J; Li J; Liu C; Liu F; Ma Y; Mao Y; Niu Z; Shen J; Shi J; Shi X; Song W; Sun HC; Tan G; Tao R; Wang X; Wen T; Wu L; Xia J; Xiang BD; Yan M; Ying M; Zhang L; Zhang X; Zeng ZC; Zhang Y; Zhang Z; Zhou J; Zhou C; Zhou J; Zhou L; Zhou X; Zhu J; Zhu Z; Zhang Q; Li Q; Cheng S
    Liver Cancer; 2022 Dec; 11(6):511-526. PubMed ID: 36589726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The past, present and future of conversion therapy for liver cancer.
    Song T; Lang M; Ren S; Gan L; Lu W
    Am J Cancer Res; 2021; 11(10):4711-4724. PubMed ID: 34765289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)].
    ; ;
    Zhonghua Wai Ke Za Zhi; 2023 Dec; 61(12):1035-1045. PubMed ID: 37932138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition.
    Cheng S; Chen M; Cai J;
    Oncotarget; 2017 Jan; 8(5):8867-8876. PubMed ID: 27780939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021.
    Cheung TT; Yu SC; Chan SL; Poon RTP; Kwok P; Lee AS; Tai A; Tam D; Cheung CC; Lai TW; Chia NH; Law A; Shum T; Lam YK; Lau V; Lee V; Chong C; Tang CN; Yau T
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):366-385. PubMed ID: 37351136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition).
    Liu X; Lu Y; Zhou W; Peng T; Zhou J; Bi H; Xia F; Chen X
    Liver Cancer; 2024 Aug; 13(4):355-375. PubMed ID: 39114757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):16-34. PubMed ID: 36948846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)].
    ; ;
    Zhonghua Wai Ke Za Zhi; 2024 Nov; 62(11):984-995. PubMed ID: 39394621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.
    Wang H; Qian YW; Dong H; Cong WM
    Hepatobiliary Surg Nutr; 2024 Jun; 13(3):472-493. PubMed ID: 38911201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.